October 7, 2008
International Steering Committee for RVX-208 IVUS Trial Formed
CALGARY, Oct. 7 /PRNewswire-FirstCall/ -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce the formation of the Steering Committee for the RVX-208 Phase 2b clinical trial assessing atherosclerosis by IVUS (Intravascular Ultrasound). This is a study in Acute Coronary Syndrome patients expected to start in 2009.
"We are honored to have an experienced and highly esteemed group of internationally recognized cardiologists to lead this important IVUS atherosclerosis study," said Mr. Donald J. McCaffrey, President and CEO of Resverlogix. "ApoA-IMilano infusions have previously been shown to be the most efficient means to reduce atherosclerosis, we will now test the hypothesis that a permanent endogenous ApoA-I increase by oral administration of RVX-208 has the same capacity".
Appointed members of the Phase 2b IVUS Steering Committee include: Chairman: Dr. Steven Nissen, M.D., Chairman of the Department of Cardiovascular Medicine located on the main campus of Cleveland Clinic. Principal Investigator: Dr. Stephen Nicholls, M.B.B.S, Ph.D., Medical Director of Intravascular Ultrasound and Angiography Core Laboratories at Cleveland Clinic and Clinical Director of the Cleveland Clinic Center for Cardiovascular Diagnostics and Prevention. Dr. Christie M. Ballantyne, M.D., Associate Chief and Professor, Section of Atherosclerosis and Lipoprotein Research, Baylor College of Medicine, Houston, Texas. Dr. John J.P. Kastelein, M.D., Ph.D., Professor of Medicine and Chairman of the Department of Vascular Medicine at the Academic Medical Centre (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease and is the Director of the Atherosclerosis Research Group. Dr. Allen Taylor, M.D., Chief, Cardiology Service, Professor of Medicine, USUHS Walter Reed Army Medical Center in Washington, D.C.The role of the Steering Committee is to provide overall supervision of the trial and ensure that it is being conducted in accordance with the principles of Good Clinical Practice and FDA regulations. The Steering Committee will agree on the trial protocol, any protocol amendments and provide advice to the investigators on all aspects of the trial.
Apolipoprotein A-I (ApoA-I), the main component of high-density lipoprotein (HDL) represent the body's natural defense system against atherosclerosis by mediating reverse cholesterol transport, i.e. transport of peripheral cholesterol including that of the vessel wall to the liver for elimination from the body. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in animals and humans.
RVX-208, a novel small molecule drug that facilitates endogenous ApoA-I production, is positioned as an emerging drug that holds the most promise for the treatment of atherosclerosis. RVX-208 is designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's disease and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com/.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
CONTACT: Theresa Kennedy, VP, Corporate Communications, ResverlogixCorp., Phone: (604) 538-7072, Email: [email protected]; DonaldMcCaffrey, President & CEO, Resverlogix Corp., Phone: (403) 254-9252, Email:[email protected]; Website: http://www.resverlogix.com/